^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CA-170

i
Other names: AUPM170, AUPM 170, CA-170 , AUPM-170, CA 170, CA170
Associations
Company:
Curis, Dr. Reddy’s
Drug class:
PD-L1 inhibitor, VISTA antagonist
Related drugs:
Associations
over4years
New emerging targets in cancer immunotherapy: the role of VISTA. (PubMed, ESMO Open)
Particularly, CA-170, an orally delivered dual inhibitor of VISTA and PD-L1, has shown to have clinical efficacy in phase I and II clinical trials in different advanced solid tumour types. Further data are needed to define whether this drug class can become a new therapeutic option for patients with VISTA expressing cancers.
Review • Journal • PD(L)-1 Biomarker
|
PD-1 (Programmed cell death 1)
|
CA-170